[1] MAHMOODI B K,TEN K M K,WAANDERS F,et al.High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome:results from a large retrospective cohort study[J].Circulation,2008,117(2):224-230.
[2] BAUER A,LIMPERGER V,NOWAK-GOTTL U.End-stage renal disease and thrombophilia[J].Hamostaseologie,2015.
[3] VERHAVE J C,TAGALAKIS V,SUISSA S,et al.The risk of thromboembolic events in kidney transplant patients[J].Kidney Int,2014,85(6):1454-1460.
[4] FOLSOM A R,LUTSEY P L,ASTOR B C,et al.Chronic kidney disease and venous thromboembolism:a prospective study[J].Nephrol Dial Transplant,2010,25(10):3296-3301.
[5] PARIKH A M,SPENCER F A,LESSARD D,et al.Venous thromboembolism in patients with reduced estimated GFR:a population-based perspective [J].Am J Kidney Dis,2011,58(5):746-755.
[6] NIMMO C,WRIGHT M,GOLDSMITH D.Management of atrial fibrillation in chronic kidney disease:double trouble[J].Am Heart J,2013,166(2): 230-239.
[7] 王志敬,张立娟,周茂峰.心房颤动抗栓治疗新进展[J].现代医学,2011,39(6):747-750.
[8] NG K P,EDWARDS N C,LIP G Y,et al.Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation[J].Am J Kidney Dis,2013,62(3):615-632.
[9] KONSTANTINIDES S V,TORBICKI A,AGNELLI G,et al.2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism[J].Eur Heart J,2014,35(43):3033-3069.
[10] KEELING D,BAGLIN T,TAIT C,et al.Guidelines on oral anticoagulation with warfarin-fourth edition[J].Br J Haematol,2011,154(3):311-324.
[11] LIMDI N A,BEASLEY T M,BAIRD M F,et al.Kidney function influences warfarin responsiveness and hemorrhagic complications[J].J Am Soc Nephrol,2009,20(4):912-921.
[12] SUZUKI M,MATSUE Y,NAKAMURA R,et al.Improvement of HAS-BLED bleeding score predictive capability by changing the definition of renal dysfunction in Japanese atrial fibrillation patients on anticoagulation therapy[J].J Cardiol,2014,64(6):482-487.
[13] van BLIJDERVEEN J C,VERHAMME K M,ZIETSE R,et al.Overanticoagulation is associated with renal function decline[J].J Nephrol,2013,26(4):691-698.
[14] GENOVESI S,ROSSI E,GALLIENI M,et al.Warfarin use,mortality,bleeding and stroke in haemodialysis patients with atrial fibrillation[J].Nephrol Dial Transplant,2015,30(3):491-498.
[15] CHAN K E,LAZARUS J M,THADHANI R,et al.Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation[J].J Am Soc Nephrol,2009,20(10):2223-2233.
[16] CHAN K E,LAZARUS J M,THADHANI R,et al.Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients[J].J Am Soc Nephrol,2009,20(4):872-881.
[17] JUMA S,THOMSON B K,LOK C E,et al.Warfarin use in hemodialysis patients with atrial fibrillation: decisions based on uncertainty [J].BMC Nephrol,2013,14:174.
[18] AGENO W,GALLUS A S,WITTKOWSKY A,et al.Oral anticoagulant therapy:antithrombotic therapy and prevention of thrombosis,9th ed:american college of chest physicians evidence-based clinical practice guidelines[J].Chest,2012,141(2 Suppl):e44S-88S.
[19] HART R G,EIKELBOOM J W,INGRAM A J,et al.Anticoagulants in atrial fibrillation patients with chronic kidney disease[J].Nat Rev Nephrol,2012,8(10):569-578.
[20] WIENEN W,STASSEN J M,PRIEPKE H,et al.In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug,dabigatran etexilate[J].Thromb Haemost,2007,98(1):155-162.
[21] CONNOLLY S J,EZEKOWITZ M D,YUSUF S,et al.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2009,361(12):1139-1151.
[22] FELLOWS S E,ROSINI J M,CURTIS J A,et al.Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency[J].J Emerg Med,2013,44(2):e221-e225.
[23] WYCHOWSKI M K,KOUIDES P A.Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment[J].Ann Pharmacother,2012,46(4):e10.
[24] KERNAN L,ITO S,SHIRAZI F,et al.Fatal gastrointestinal hemorrhage after a single dose of dabigatran[J].Clin Toxicol (Phila),2012,50(7):571-573.
[25] U.S.Food and Drug Administration.FDA approved drug products:Xarelto.http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&Drug Name=XARELTO(2011).
[26] PATEL M R,MAHAFFEY K W,GARG J,et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J].N Engl J Med,2011,365(10): 883-891.
[27] FOX K A,PICCINI J P,WOJDYLA D,et al.Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment[J].Eur Heart J,2011,32(19):2387-2394.
[28] Bristol Myers Squibb Company,princeton,New Jersey,2012.product Information:eliquis Oral tablets,apixaban Oral tablets.http://www.rxlist.com/eliquis-drug.htm
[29] GRANGER C B,ALEXANDER J H,MCMURRAY J J,et al.Apixaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2011,365(11):981-992.
[30] LAM S.Apixaban:a new factor Ⅹa inhibitor for stroke prevention in patients with nonvalvular atrial fibrillation[J].Cardiol Rev,2013,21(4):207-212.
[31] SALIM I,AL S J,GHADBAN W,et al.Anticoagulation in atrial fibrillation and co-existent chronic kidney disease:efficacy versus safety[J].Expert Opin Drug Saf,2013,12(1):53-63.
[32] HAREL Z,SHOLZBERG M,SHAH P S,et al.Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD[J].J Am Soc Nephrol,2014,25(3):431-442. |
